Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% Higher – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares rose 5.2% during trading on Monday . The stock traded as high as $40.99 and last traded at $40.99. Approximately 84,013 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 714,662 shares. The stock had previously closed at $38.97.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AGIO. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Down 1.7 %

The stock has a market capitalization of $2.39 billion, a PE ratio of 3.69 and a beta of 0.80. The business’s 50-day moving average is $50.09 and its two-hundred day moving average is $46.84.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Exome Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 3rd quarter valued at $2,941,000. Franklin Resources Inc. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth about $1,499,000. Geode Capital Management LLC boosted its holdings in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after purchasing an additional 6,101 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in Agios Pharmaceuticals by 19.7% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after purchasing an additional 172,180 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in Agios Pharmaceuticals by 56.2% during the 3rd quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company’s stock worth $370,000 after purchasing an additional 2,996 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.